Koyfin Home > Directory > Health Care > Akebia Therapeutics > Capital Expenditures

Akebia Therapeutics Capital Expenditures Chart (AKBA)

Akebia Therapeutics annual/quarterly Capital Expenditures from 2013 to 2020.
  • Akebia Therapeutics Capital Expenditures for the quarter ending June 06, 2020 was $0m a -4,295.56% increase of 2m year over year
  • Akebia Therapeutics Capital Expenditures for the last 12 months ending June 06, 2020 was $-3m a -160.02% increase of 4m year over year
  • Akebia Therapeutics Annual Capital Expenditures for 2019 was $-7m a 75.87% decrease of -5m from 2018
  • Akebia Therapeutics Annual Capital Expenditures for 2018 was $-2m a -1.00% increase of 0m from 2017
  • Akebia Therapeutics Annual Capital Expenditures for 2017 was $-2m a -64.12% increase of 1m from 2016
Other Cash Flow Metrics:
  • Akebia Therapeutics Cash Flow from Operations for the quarter ending December 12, 2018 was $-74m a 72.41% decrease of -53m year over year
  • Akebia Therapeutics Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-92m a 89.67% decrease of -82m year over year
  • Akebia Therapeutics Total Revenue for the quarter ending December 12, 2018 was $60m a 23.26% increase of 14m year over year
View Chart On Koyfin

Quarterly AKBA Capital Expenditures Data

06/2020$0m
12/2019$0m
09/2019$-3m
06/2019$-2m
03/2019$-2m
12/2018$-1m
09/2018$0m
06/2018$0m
03/2018$0m
12/2017$0m

Annual AKBA Capital Expenditures Data

2019$-7m
2018$-2m
2017$-2m
2016$-3m
2015$0m
2014$0m
2013$0m
2011$0m